1. Home
  2. UG vs IRD Comparison

UG vs IRD Comparison

Compare UG & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UG
  • IRD
  • Stock Information
  • Founded
  • UG 1942
  • IRD 2018
  • Country
  • UG United States
  • IRD United States
  • Employees
  • UG N/A
  • IRD N/A
  • Industry
  • UG Package Goods/Cosmetics
  • IRD
  • Sector
  • UG Consumer Discretionary
  • IRD
  • Exchange
  • UG Nasdaq
  • IRD NYSE
  • Market Cap
  • UG 36.8M
  • IRD 38.8M
  • IPO Year
  • UG N/A
  • IRD N/A
  • Fundamental
  • Price
  • UG $8.06
  • IRD $0.95
  • Analyst Decision
  • UG
  • IRD Strong Buy
  • Analyst Count
  • UG 0
  • IRD 2
  • Target Price
  • UG N/A
  • IRD $7.00
  • AVG Volume (30 Days)
  • UG 12.6K
  • IRD 184.2K
  • Earning Date
  • UG 05-08-2025
  • IRD 05-15-2025
  • Dividend Yield
  • UG 8.70%
  • IRD N/A
  • EPS Growth
  • UG 4.82
  • IRD N/A
  • EPS
  • UG 0.63
  • IRD N/A
  • Revenue
  • UG $11,408,154.00
  • IRD $10,992,000.00
  • Revenue This Year
  • UG N/A
  • IRD $22.00
  • Revenue Next Year
  • UG N/A
  • IRD $100.89
  • P/E Ratio
  • UG $12.79
  • IRD N/A
  • Revenue Growth
  • UG N/A
  • IRD N/A
  • 52 Week Low
  • UG $7.73
  • IRD $0.65
  • 52 Week High
  • UG $16.25
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • UG 42.37
  • IRD N/A
  • Support Level
  • UG $7.84
  • IRD N/A
  • Resistance Level
  • UG $8.44
  • IRD N/A
  • Average True Range (ATR)
  • UG 0.38
  • IRD 0.00
  • MACD
  • UG 0.04
  • IRD 0.00
  • Stochastic Oscillator
  • UG 24.52
  • IRD 0.00

About UG United-Guardian Inc.

United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: